In turn, localized approaches such as microneedles and hydrogels restrict STING activation to the tumor site, lowering the risk of systemic cytokine release and immune-related toxicity while maintaining synergistic efficacy in combination with PD-1/PD-L1 blockade [106,107,108,115,116,117]. The gene discussed is STING1; the disease is neoplasm.